ALPHA TAU MEDICAL LTD (DRTS) Fundamental Analysis & Valuation

NASDAQ:DRTS • IL0011839383

Current stock price

6.92 USD
0 (0%)
Last:

This DRTS fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. DRTS Profitability Analysis

1.1 Basic Checks

  • In the past year DRTS has reported negative net income.
  • In the past year DRTS has reported a negative cash flow from operations.
  • DRTS had negative earnings in each of the past 5 years.
  • DRTS had a negative operating cash flow in each of the past 5 years.
DRTS Yearly Net Income VS EBIT VS OCF VS FCFDRTS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 2025 -10M -20M -30M -40M

1.2 Ratios

  • DRTS has a Return On Assets of -40.35%. This is in the lower half of the industry: DRTS underperforms 63.30% of its industry peers.
  • DRTS has a Return On Equity of -55.29%. This is comparable to the rest of the industry: DRTS outperforms 48.94% of its industry peers.
Industry RankSector Rank
ROA -40.35%
ROE -55.29%
ROIC N/A
ROA(3y)-34.78%
ROA(5y)-39.41%
ROE(3y)-46.82%
ROE(5y)-62.89%
ROIC(3y)N/A
ROIC(5y)N/A
DRTS Yearly ROA, ROE, ROICDRTS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 2025 -50 -100

1.3 Margins

  • DRTS does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
DRTS Yearly Profit, Operating, Gross MarginsDRTS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 2025

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. DRTS Health Analysis

2.1 Basic Checks

  • DRTS has more shares outstanding than it did 1 year ago.
  • DRTS has more shares outstanding than it did 5 years ago.
  • The debt/assets ratio for DRTS has been reduced compared to a year ago.
DRTS Yearly Shares OutstandingDRTS Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M
DRTS Yearly Total Debt VS Total AssetsDRTS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M

2.2 Solvency

  • An Altman-Z score of 9.73 indicates that DRTS is not in any danger for bankruptcy at the moment.
  • The Altman-Z score of DRTS (9.73) is better than 88.83% of its industry peers.
  • A Debt/Equity ratio of 0.08 indicates that DRTS is not too dependend on debt financing.
  • Looking at the Debt to Equity ratio, with a value of 0.08, DRTS is in the better half of the industry, outperforming 66.49% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.08
Debt/FCF N/A
Altman-Z 9.73
ROIC/WACCN/A
WACCN/A
DRTS Yearly LT Debt VS Equity VS FCFDRTS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 2025 0 20M -20M 40M 60M 80M 100M

2.3 Liquidity

  • DRTS has a Current Ratio of 7.45. This indicates that DRTS is financially healthy and has no problem in meeting its short term obligations.
  • DRTS has a Current ratio of 7.45. This is amongst the best in the industry. DRTS outperforms 87.23% of its industry peers.
  • A Quick Ratio of 7.45 indicates that DRTS has no problem at all paying its short term obligations.
  • With an excellent Quick ratio value of 7.45, DRTS belongs to the best of the industry, outperforming 89.89% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 7.45
Quick Ratio 7.45
DRTS Yearly Current Assets VS Current LiabilitesDRTS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. DRTS Growth Analysis

3.1 Past

  • DRTS shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -4.44%.
EPS 1Y (TTM)-4.44%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%38.46%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • DRTS is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 35.20% yearly.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-4.28%
EPS Next 2Y9.64%
EPS Next 3Y26.45%
EPS Next 5Y35.2%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
DRTS Yearly Revenue VS EstimatesDRTS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2026 2027 2028 2029 2030 50M 100M 150M 200M 250M
DRTS Yearly EPS VS EstimatesDRTS Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 0.5 -0.5 1

More info and screens

Find the best growth stocksShow best growing peers

1

4. DRTS Valuation Analysis

4.1 Price/Earnings Ratio

  • DRTS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for DRTS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
DRTS Price Earnings VS Forward Price EarningsDRTS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
DRTS Per share dataDRTS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 -0.4 0.6 0.8

4.3 Compensation for Growth

  • DRTS's earnings are expected to grow with 26.45% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y9.64%
EPS Next 3Y26.45%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. DRTS Dividend Analysis

5.1 Amount

  • DRTS does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

DRTS Fundamentals: All Metrics, Ratios and Statistics

ALPHA TAU MEDICAL LTD

NASDAQ:DRTS (4/2/2026, 8:19:47 PM)

6.92

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)03-09
Earnings (Next)N/A
Inst Owners3.37%
Inst Owner Change22.55%
Ins Owners16.16%
Ins Owner Change0%
Market Cap609.03M
Revenue(TTM)N/A
Net Income(TTM)-42.63M
Analysts86
Price Target9.69 (40.03%)
Short Float %0.95%
Short Ratio1.84
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)8.7%
Min EPS beat(2)-19.09%
Max EPS beat(2)36.49%
EPS beat(4)2
Avg EPS beat(4)3.35%
Min EPS beat(4)-19.09%
Max EPS beat(4)36.49%
EPS beat(8)5
Avg EPS beat(8)6.89%
EPS beat(12)8
Avg EPS beat(12)9.04%
EPS beat(16)11
Avg EPS beat(16)-19.65%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)15.15%
PT rev (3m)15.15%
EPS NQ rev (1m)-3.89%
EPS NQ rev (3m)-3.89%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)119.25%
Revenue NQ rev (3m)119.25%
Revenue NY rev (1m)-40.94%
Revenue NY rev (3m)-40.94%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 7.9
P/tB 7.9
EV/EBITDA N/A
EPS(TTM)-0.47
EYN/A
EPS(NY)-0.49
Fwd EYN/A
FCF(TTM)-0.37
FCFYN/A
OCF(TTM)-0.3
OCFYN/A
SpS0
BVpS0.88
TBVpS0.88
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -40.35%
ROE -55.29%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-34.78%
ROA(5y)-39.41%
ROE(3y)-46.82%
ROE(5y)-62.89%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.08
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 493.1%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.45
Quick Ratio 7.45
Altman-Z 9.73
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)430.73%
Cap/Depr(5y)351.93%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-4.44%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%38.46%
EPS Next Y-4.28%
EPS Next 2Y9.64%
EPS Next 3Y26.45%
EPS Next 5Y35.2%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-17.33%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-5.2%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-48.75%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-34.87%
OCF growth 3YN/A
OCF growth 5YN/A

ALPHA TAU MEDICAL LTD / DRTS Fundamental Analysis FAQ

What is the fundamental rating for DRTS stock?

ChartMill assigns a fundamental rating of 2 / 10 to DRTS.


What is the valuation status for DRTS stock?

ChartMill assigns a valuation rating of 1 / 10 to ALPHA TAU MEDICAL LTD (DRTS). This can be considered as Overvalued.


How profitable is ALPHA TAU MEDICAL LTD (DRTS) stock?

ALPHA TAU MEDICAL LTD (DRTS) has a profitability rating of 0 / 10.


What is the earnings growth outlook for ALPHA TAU MEDICAL LTD?

The Earnings per Share (EPS) of ALPHA TAU MEDICAL LTD (DRTS) is expected to decline by -4.28% in the next year.